Centessa Pharmaceuticals (CNTA) EBIAT: 2022-2025
Historic EBIAT for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$54.9 million.
- Centessa Pharmaceuticals' EBIAT fell 28.96% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 50.50%. This contributed to the annual value of -$235.8 million for FY2024, which is 56.04% down from last year.
- According to the latest figures from Q3 2025, Centessa Pharmaceuticals' EBIAT is -$54.9 million, which was down 9.03% from -$50.3 million recorded in Q2 2025.
- In the past 5 years, Centessa Pharmaceuticals' EBIAT registered a high of -$24.9 million during Q2 2023, and its lowest value of -$111.3 million during Q4 2024.
- Moreover, its 3-year median value for EBIAT was -$42.6 million (2024), whereas its average is -$47.1 million.
- Per our database at Business Quant, Centessa Pharmaceuticals' EBIAT spiked by 61.51% in 2023 and then slumped by 202.22% in 2024.
- Quarterly analysis of 4 years shows Centessa Pharmaceuticals' EBIAT stood at -$43.2 million in 2022, then increased by 14.68% to -$36.8 million in 2023, then crashed by 202.22% to -$111.3 million in 2024, then fell by 28.96% to -$54.9 million in 2025.
- Its last three reported values are -$54.9 million in Q3 2025, -$50.3 million for Q2 2025, and -$26.1 million during Q1 2025.